CAMs are used for the prevention and treatment of infectious and inflammatory diseases, though for many of these CAMs, their true efficacy and the molecular basis for their purported benefits have not been defined and/or confirmed. We propose a new Center of Excellence for Research on CAMs (CERC) focused on the study of the mechanisms of action of diverse CAMs in models of pulmonary and intestinal infectious disease. Since in many instances the resulting inflammatory response associated with infection in the lung and intestinal track accounts for the actual pathology in the disease, we also intend to expand ongoing efforts in using CAMs to minimize inflammation induced tissue damage. The ultimate goal of this CERC is to provide critical insight into the mechanisms of action of select CAMs that can be used as countermeasures against emerging and select agents that infect the pulmonary and intestinal mucosa. This Center brings together scientists with expertise in bacterial and viral diseases of the lung and intestinal tract, study of CAM effects on innate leukocytes and epithelial cells, purification of defined agonists from crude plant extracts, use of probiotic CAMs, and use of rodent models of infectious and inflammatory disease to define specific mechanisms of action. This Center will also take advantage of new BSL-3 facilities to study the impact of CAMs on select agents. The CERC will initially be focused on three distinct projects, which will be supported by two Cores: Administrative (Core A) and Animal Model (Core B). The three Research Projects are: Project 1) CAMs that enhance ??T cell function, Project Leader, Mark Jutila, Ph.D.;Project 2) Anti-viral CAMs, Project Leader, Dr. Michele Hardy, Ph.D.;and Project 3) Anti-inflammatory microbial CAMs and arthritis, Project Leader, Dr. David Pascual, Ph.D. The Animal Models Core will serve as a unique and highly interactive resource, facilitating synergy and collaboration between the three research projects.

Public Health Relevance

CAMs are widely used by the public to treat a variety of ailments, however, in many instances their true efficacy, safety and specific mechanisms of action are unknown. This proposed CERC provides a unique focus on mechanistic studies of CAMs that counter infectious and inflammatory disease. It directly addresses the goals of the NCCAM, and will provide important new information relevant to the use of CAMs by the public.

Agency
National Institute of Health (NIH)
Institute
National Center for Complementary & Alternative Medicine (NCCAM)
Type
Research Program Projects (P01)
Project #
5P01AT004986-03
Application #
7920835
Study Section
Special Emphasis Panel (ZAT1-SM (11))
Program Officer
Pontzer, Carol H
Project Start
2008-09-30
Project End
2013-08-31
Budget Start
2010-09-01
Budget End
2011-08-31
Support Year
3
Fiscal Year
2010
Total Cost
$1,188,000
Indirect Cost
Name
Montana State University - Bozeman
Department
Veterinary Sciences
Type
Schools of Earth Sciences/Natur
DUNS #
625447982
City
Bozeman
State
MT
Country
United States
Zip Code
59717
Hedges, Jodi F; Robison, Amanda; Kimmel, Emily et al. (2016) Type I Interferon Counters or Promotes Coxiella burnetii Replication Dependent on Tissue. Infect Immun 84:1815-1825
Ramstead, Andrew G; Schepetkin, Igor A; Todd, Kimberly et al. (2015) Aging influences the response of T cells to stimulation by the ellagitannin, oenothein B. Int Immunopharmacol 26:367-77
Hedges, Jodi F; Mitchell, Angela M; Jones, Kerri et al. (2015) Amphotericin B stimulates ?? T and NK cells, and enhances protection from Salmonella infection. Innate Immun 21:598-608
Maddaloni, Massimo; Kochetkova, Irina; Jun, SangMu et al. (2015) Milk-based nutraceutical for treating autoimmune arthritis via the stimulation of IL-10- and TGF-?-producing CD39+ regulatory T cells. PLoS One 10:e0117825
Hendricks, Jay M; Lowe, Diana C; Hardy, Michele E (2014) Differential induction of isolated lymphoid follicles in the gut by 18?-glycyrrhetinic acid. PLoS One 9:e100878
Pascual, David W; Yang, Xinghong; Holderness, Kathryn et al. (2014) Regulatory T-cell vaccination independent of auto-antigen. Exp Mol Med 46:e82
Kochetkova, Irina; Thornburg, Theresa; Callis, Gayle et al. (2014) Oral Escherichia coli colonization factor antigen I fimbriae ameliorate arthritis via IL-35, not IL-27. J Immunol 192:804-16
Snyder, Deann T; Robison, Amanda; Kemoli, Sharon et al. (2014) Oral delivery of oligomeric procyanidins in Apple Poly® enhances type I IFN responses in vivo. J Leukoc Biol 95:841-847
Skyberg, Jerod A (2014) Immunopotentiation for bacterial biodefense. Curr Top Med Chem 14:2115-26
Hedges, Jodi F; Kimmel, Emily; Snyder, Deann T et al. (2013) Solute carrier 11A1 is expressed by innate lymphocytes and augments their activation. J Immunol 190:4263-73

Showing the most recent 10 out of 32 publications